Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CurveBeam AIASX:CVB Days Sales Outstanding is 163.63 as of Jun. 2026, which is 108% above its 10-year median of 78.48. The stock has 8 warning signs investors should review. Among 809 Medical Devices & Instruments companies, CurveBeam AI ranks worse than 76.76% on this metric.
CurveBeam AI's average Accounts Receivable for the
six
months ended in Jun. 2026 was A$3.32 Mil. CurveBeam AI's Revenue for the
six
months ended in Jun. 2026 was A$3.71 Mil.
Hence, CurveBeam AI's Days Sales Outstanding for the
six
months ended in Jun. 2026 was 163.63.
The historical rank and industry rank for CurveBeam AI's Days Sales Outstanding or its related term are showing as below:
ASX:CVB'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.51 Med: 78.48 Max: 132.59
Current: 96.69
During the past 6 years, CurveBeam AI's highest Days Sales Outstanding was 132.59. The lowest was 12.51. And the median was 78.48.
ASX:CVB's Days Sales Outstanding is ranked worse than 76.76% of 809
companies
in the Medical Devices & Instruments industry
Industry Median: 64.94
vs ASX:CVB: 96.69
CurveBeam AI's Days Sales Outstanding
increased
from Jun. 2025 (27.73) to Jun. 2026 (163.63).
CurveBeam AI (ASX:CVB) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
CurveBeam AI Days Sales Outstanding Related Terms
CurveBeam AI Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for CurveBeam AI's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CVB vs ABT, SYK, MDT: Days Sales Outstanding Comparison
For the Medical Devices subindustry, CurveBeam AI's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CurveBeam AI Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CurveBeam AI's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where CurveBeam AI's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 163.63 mean?
CurveBeam AI (ASX:CVB) has a Days Sales Outstanding of 163.63 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on CurveBeam AI and its competitors. This is 108% above median its historical median of 78.48. Over the past decade, CurveBeam AI's Days Sales Outstanding has ranged from 12.51 to 132.59. According to the industry distribution chart, CurveBeam AI ranks #621 out of 809 companies in the Medical Devices & Instruments industry, placing it in the top 76.8%.
Is CurveBeam AI's Days Sales Outstanding too high?
CurveBeam AI's current Days Sales Outstanding of 163.63 is 108% above median its 10-year median of 78.48. Over the past 10 years, this metric has ranged from a low of 12.51 to a high of 132.59. The Medical Devices & Instruments industry median Days Sales Outstanding is 64.94. CurveBeam AI's value of 163.63 is 152% above this industry median. Based on the distribution chart, CurveBeam AI ranks #621 out of 809 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does CurveBeam AI's Days Sales Outstanding compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CurveBeam AI ranks #621 out of 809 companies for Days Sales Outstanding. This places CurveBeam AI in the lower half of its industry. The industry median Days Sales Outstanding is 64.94. CurveBeam AI's value of 163.63 is 152% above this benchmark. Historically, CurveBeam AI's own Days Sales Outstanding has ranged from 12.51 to 132.59 over the past decade. While the company's 10-year median is 78.48 vs. the industry median of 64.94, CurveBeam AI has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 64.94, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CurveBeam AI's current Days Sales Outstanding of 163.63 is 152% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on CurveBeam AI and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 64.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CurveBeam AI's current Days Sales Outstanding is 163.63, which is 108% above median its own 10-year median of 78.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CurveBeam AI stock overvalued right now?
Based on GuruFocus' analysis, CurveBeam AI (ASX:CVB) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.06, compared to a current price of A$0.02 — trading 66.7% below its estimated fair value. The current Days Sales Outstanding is 163.63, which is 108% above median its 10-year median of 78.48 and 152% above the Medical Devices & Instruments industry median of 64.94. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For CurveBeam AI (ASX:CVB), the current Days Sales Outstanding is 163.63 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company's CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CVB has been successfully added to your 
